SXSW 2020
Cannabis Biotech: The New Wave of Pharma
Description:
We are at the start of a new era, the Second Generation of marijuana-based medicine. Many pharmaceutical companies aim to emulate the success of GW Pharmaceuticals with its FDA approval of Epidiolex. Drugmakers are entering the game to treat a variety of conditions like arthritis, epilepsy, Crohn's disease and MS. So what is the science behind creating pharmaceutical grade drugs with cannabis, what are the FDA hurdles, how do you get funding for cannabis research, and what are the top ailments that will be successfully treated?
Related Media
Takeaways
- Biotech are synthesizing weed. What does the new science of biosynthesis mean for the industry?
- Cannabis dosage has been a very difficult issue for medical experts. How will these new drugs handle dosage?
- The economics of pharma and weed: what are companies currently doing, and what are their key targets for treatment?
Speakers
- Jonathan Rothbard, CEO/Co-Founder, Katexco Pharmaceuticals
- William Levine, Chief Science Officer and founder, CannRx
- Glenn Copeland, CEO, Chairman, Founder, Copeland Biosciences
- Daniel Fabricant, president of the Natural Products Association, Natural Products Association
Organizer
Aaron Smith, Senior Account Executive, KCSA Strategic Communciations
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments